Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Takeda’s Alogliptin Strategy: Treatment Options

This article was originally published in The Pink Sheet Daily

Executive Summary

With five Phase III wins for type 2 diabetes, company plans to build on Actos’ success.

You may also be interested in...



Onglyza Stacks Up To Januvia, Bristol/AstraZeneca Say

Onglyza efficacy is competitive with other DPP-4 inhibitors, Bristol-Myers Squibb/AstraZeneca say - Partners say new data on saxagliptin efficacy, presented at EASD in Rome, show competitive profile and are preparing a head-to-head trial with Merck's Januvia. Onglyza and Takeda's alogliptin could join Januvia on the market in the next year, but it's not clear how the new drugs will be differentiated. Heightened scrutiny of diabetes drug safety could help Merck maintain an advantage

Onglyza Stacks Up To Januvia, Bristol/AstraZeneca Say

Onglyza efficacy is competitive with other DPP-4 inhibitors, Bristol-Myers Squibb/AstraZeneca say - Partners say new data on saxagliptin efficacy, presented at EASD in Rome, show competitive profile and are preparing a head-to-head trial with Merck's Januvia. Onglyza and Takeda's alogliptin could join Januvia on the market in the next year, but it's not clear how the new drugs will be differentiated. Heightened scrutiny of diabetes drug safety could help Merck maintain an advantage

Onglyza Stacks Up To Januvia, Bristol/AstraZeneca Say

Merck has held a monopoly on the dipeptidyl peptidase-4 inhibitor market for type 2 diabetes since launching Januvia (sitagliptin)in 2006 - a franchise that's now approaching blockbuster status - but within the next year it could be sharing scripts with two new rivals

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS067887

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel